AZTA vs NTLA

AZTA exhibits mixed financial health with a weak Piotroski F-Score of 4/9, indicating borderline stability, and lacks an Altman Z-Score to assess distress risk. While the company shows strong revenue visibility and improving earnings trends, elevated valuation metrics (P/E of 77.02 vs. sector average of 220.68) and negative profit margins (-9.39%) raise concerns. Recent insider selling and declining long-term price performance contrast with a positive short-term rebound and solid quarterly earnings surprises. The stock trades significantly above the Graham Number of $20.99, suggesting potential overvaluation relative to defensive criteria.

Intellia Therapeutics exhibits severe fundamental weakness, highlighted by a Piotroski F-Score of 1/9, indicating poor financial health and operational inefficiency. While the company maintains a strong liquidity position with a current ratio of 5.08 and low debt, it is plagued by massive operating losses (-428.86% margin) and a prohibitively high Price/Sales ratio of 26.08. Despite strong YoY revenue growth and positive analyst price targets, the combination of bearish insider selling and a long-term 5-year price decline of 78.8% suggests a high-risk speculative profile rather than a value investment.